- Home
- SHOT vs FGEN Comparison
SHOT vs FGEN Comparison
Compare SHOT & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- FGEN
- Stock Information
- Founded
- SHOT 2018
- FGEN 1993
- Country
- SHOT United States
- FGEN United States
- Employees
- SHOT N/A
- FGEN N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- FGEN Health Care
- Exchange
- SHOT Nasdaq
- FGEN Nasdaq
- Market Cap
- SHOT 30.4M
- FGEN 33.5M
- IPO Year
- SHOT 2020
- FGEN 2014
- Fundamental
- Price
- SHOT $0.39
- FGEN $5.62
- Analyst Decision
- SHOT
- FGEN Strong Buy
- Analyst Count
- SHOT 0
- FGEN 1
- Target Price
- SHOT N/A
- FGEN $250.00
- AVG Volume (30 Days)
- SHOT 6.1M
- FGEN 60.4K
- Earning Date
- SHOT 08-13-2025
- FGEN 08-05-2025
- Dividend Yield
- SHOT N/A
- FGEN N/A
- EPS Growth
- SHOT N/A
- FGEN N/A
- EPS
- SHOT N/A
- FGEN N/A
- Revenue
- SHOT $573,336.00
- FGEN $6,996,000.00
- Revenue This Year
- SHOT N/A
- FGEN N/A
- Revenue Next Year
- SHOT N/A
- FGEN N/A
- P/E Ratio
- SHOT N/A
- FGEN N/A
- Revenue Growth
- SHOT 69.32
- FGEN N/A
- 52 Week Low
- SHOT $0.23
- FGEN $4.50
- 52 Week High
- SHOT $1.77
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- SHOT 55.28
- FGEN 40.90
- Support Level
- SHOT $0.35
- FGEN $5.37
- Resistance Level
- SHOT $0.48
- FGEN $5.73
- Average True Range (ATR)
- SHOT 0.07
- FGEN 0.49
- MACD
- SHOT 0.02
- FGEN 0.03
- Stochastic Oscillator
- SHOT 53.64
- FGEN 37.56
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.